Oscar Health, Inc. (OSCR) Stock Analysis
Is OSCR a good investment?
Oscar Health, Inc. (OSCR) has a Plutrex AI rating of 69.0/100 as of October 10, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: Fortress balance sheet: $8.56B cash + $4.33B annual FCF with D/E of 0.21 — 72% below industry average of 0.75 — provides exceptional resilience against claims volatility and strategic optionality; ROE of 34.31% is nearly 4x the industry average of 9.09% achieved without leverage. Main concern: Medical loss ratio / thin margin risk: Net margin of only 3.6% and operating margin of 8.0% leave minimal buffer against rising medical costs — a 200-300 bps deterioration in the MLR could eliminate profitability entirely; this is not theoretical but an active sector-wide trend in 2025-2026; headline 'Can Oscar Health Turn ACA Marketplace Growth Into Lasting Profits?' explicitly questions sustainability of margin in a growth-at-scale environment.
Investment Summary
Oscar Health (OSCR) at $33.37 remains a compelling long-term story but the 12.7% price appreciation since my prior report ($29.60 → $33.37) has meaningfully compressed the margin of safety and risk/reward. The stock now trades at a P/E of 24.37x vs. 21.62x prior — a 12.7% multiple expansion — while the analyst consensus target remains anchored at $39.33, shrinking upside from 32.9% to 17.9%. The implied 1-year forward PEG has risen from ~0.94 to ~1.06, moving from clearly undervalued to approximately fair value on a growth-adjusted basis. Core fundamentals remain exceptional: ROE of 34.31% (vs. industry 9.09%), D/E of 0.21 (vs. industry 0.75), $8.56B cash, $4.33B FCF, revenue growth of 70.4% (vs. industry 5.06%), and forward EPS growth of 22.92% (vs. industry 17.81%). News sentiment is strongly positive at 87.5/100: Oscar grew membership 60% while the overall ACA market contracted 13%, achieving 30% market share — an extraordinary countertrend performance. However, the key risk remains the thin 3.6% net margin and 8.0% operating margin, where rising medical costs (MLR headwinds) could rapidly erode profitability. At current prices, the stock is fairly valued rather than the attractive entry it represented at $29.60.
Key Strengths
- Fortress balance sheet: $8.56B cash + $4.33B annual FCF with D/E of 0.21 — 72% below industry average of 0.75 — provides exceptional resilience against claims volatility and strategic optionality; ROE of 34.31% is nearly 4x the industry average of 9.09% achieved without leverage
- Extraordinary growth leadership: Revenue growth of 70.4% vs. industry 5.06% (~14x faster); forward EPS growth of 22.92% vs. industry 17.81% (+511 bps); Oscar grew membership 60% while ACA market contracted 13%, achieving 30% market share — demonstrating powerful competitive positioning in a shrinking total addressable market
- Growth-adjusted valuation still attractive vs. peers: Implied forward PEG of ~1.06 represents a ~44% discount to the industry average PEG of 1.92x despite a 15.1% PE premium, meaning OSCR is growth-adjusted cheaper than most competitors even after the 12.7% price appreciation since the prior report
Key Concerns
- Medical loss ratio / thin margin risk: Net margin of only 3.6% and operating margin of 8.0% leave minimal buffer against rising medical costs — a 200-300 bps deterioration in the MLR could eliminate profitability entirely; this is not theoretical but an active sector-wide trend in 2025-2026; headline 'Can Oscar Health Turn ACA Marketplace Growth Into Lasting Profits?' explicitly questions sustainability of margin in a growth-at-scale environment
- Price appreciation has eroded the entry thesis: Stock rose 12.7% from $29.60 to $33.37 while analyst target held at $39.33 — upside compressed from 32.9% to 17.9%; implied forward PEG rose from ~0.94 to ~1.06; at $33.37 the stock is fairly valued rather than the clear buy it was at $29.60; new money entering here gets materially worse risk/reward
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
ROE of 34.31% is the standout metric — nearly 4x the industry average of 9.09% — demonstrating exceptional capital efficiency achieved without leverage (D/E 0.21 vs. industry 0.75). P/E of 24.37x is a 15.1% premium to the industry average of 21.17x, but the implied 1-year forward PEG of ~1.06 (P/E 24.37 / forward EPS growth 22.92%) shows this premium is barely justified — sitting right at the fair value boundary of 1.0. Compare this favorably to the industry PEG of 1.92x — OSCR still represents a ~44% discount on a growth-adjusted basis even at current elevated prices. Revenue growth of 70.4% (vs. industry 5.06%) and trailing EPS growth of 272.8% (vs. industry ~63.5%) reflect a business in transformational acceleration. Net margin of 3.60% and operating margin of 7.96% lead the sector (industry averages 1.57% and 4.75% respectively) but remain thin in absolute terms. The $8.56B cash balance and $4.33B FCF create a fortress balance sheet that provides resilience against claims volatility. Price/Book of 5.02x is elevated but mathematically justified by the 34.3% ROE — a company earning 34% on equity deserves to trade well above book value. Analyst consensus target of $39.33 implies 17.9% upside from $33.37.
News Sentiment
Oscar Health is quietly becoming one of healthcare's most surprising success stories — and Wall Street is starting to take notice. While the broader Affordable Care Act marketplace shrank by 13% as competitors retreated, Oscar grew its membership by a stunning 60%, capturing a dominant 30% market share in a contracting market. That's the kind of countertrend performance that gets investors excited. The company's momentum hasn't gone unnoticed: Zacks recently highlighted Oscar alongside financial heavyweights Prudential Financial, Assurant, and Horace Mann in its Industry Outlook report — validating Oscar's transition from startup disruptor to legitimate industry player. Meanwhile, analysts are debating whether Oscar's growth can translate into lasting profits (headline: 'Can Oscar Health Turn ACA Marketplace Growth Into Lasting Profits?'), and a separate piece asked 'Oscar Health Trading at a Premium: Why Should You Still Buy It?' — both questions that reflect a stock that has rallied hard but still has believers. Oscar was also named among three healthcare stocks still showing sector momentum, suggesting institutional interest remains firm. The big picture: Oscar has engineered something rare in health insurance — explosive growth while simultaneously achieving profitability, backed by over $8.5 billion in cash. The question isn't whether Oscar is a strong company — the data confirms it. The real debate is whether the stock's 12.7% rally over the past two weeks has already priced in much of the good news.
Risk Assessment
PRIMARY RISK: Medical Loss Ratio (MLR) deterioration — at 3.6% net margin, a 200-300 bps increase in medical costs eliminates all profitability. This is an active sector-wide trend and the single largest fundamental threat. Mitigant: $8.56B cash fortress absorbs shocks without existential risk; management has demonstrated operational discipline. SECONDARY RISK: Revenue growth deceleration — 70.4% growth is mathematically unsustainable; deceleration to 20-30% could disappoint growth investors and compress the multiple. Mitigant: Forward EPS growth of 22.92% provides a more durable metric and still leads the industry. TERTIARY RISK: Valuation compression — P/E of 24.37x leaves limited room for multiple expansion; any earnings miss at this valuation would create outsized downside vs. lower-multiple peers. Mitigant: Forward PEG ~1.06 still at the fair value boundary, with industry comparison PEG of 1.92x providing a valuation floor. POSITION SIZING: Reduced to 2.5% (from 3.0% prior) reflecting the degraded risk/reward at current prices. Stop-loss at $27.50 is -14.7% from midpoint entry of $32.25, positioned below prior support and the psychologically significant $28 level.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is OSCR a halal stock?
No, Oscar Health, Inc. (OSCR) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for OSCR?
Oscar Health, Inc. (OSCR) has a Plutrex AI rating of 69.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is OSCR a good investment?
According to Plutrex AI, OSCR has a Buy rating (69.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in OSCR?
US stocks like OSCR can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in OSCR?
Plutrex AI identifies the main risks for OSCR by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.